MWNA
MREO

Marshall Wace North America’s Mereo BioPharma MREO Stock Holding History

Marshall Wace North America’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-178,310
Closed -$467K – 1474
2020
Q3 		$467K Sell
178,310
-88,870
-33% -$260K ﹤0.01% 979
2020
Q2 		$818K Buy
+267,180
New +$471K 0.01% 810

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Marshall Wace North America's MREO Position: Q4 2020 in Review

Marshall Wace North America sold out of Mereo BioPharma (MREO) in Q4 2020, closing a stake of 178,310 shares — an estimated $467K sold.

Marshall Wace North America first reported a position in MREO in Q2 2020 and held it in 2 quarters. The position peaked at $818K in Q2 2020. 47 funds tracked by Wall St. Rank hold MREO as of Q4 2020.

  • Marshall Wace North America reported no remaining Mereo BioPharma position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 178,310 Mereo BioPharma shares in Q4 2020, an estimated $467K.
  • Marshall Wace North America first reported a position in Mereo BioPharma in Q2 2020 and held it in 2 quarters.
  • Marshall Wace North America's Mereo BioPharma position peaked at $818K in Q2 2020.
  • 47 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.